Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.

about

Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.

Item

http://www.wikidata.org/entity/Q38706993

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Emergence of CTNNB1 mutation a ...... ibitor in metastatic melanoma.

@en

type

Item

label

Emergence of CTNNB1 mutation a ...... ibitor in metastatic melanoma.

@en

prefLabel

Emergence of CTNNB1 mutation a ...... ibitor in metastatic melanoma.

@en

P1476

Emergence of CTNNB1 mutation a ...... ibitor in metastatic melanoma.

@en

P2093

J Cho

http://www.w3.org/2001/XMLSchema#string

J H Kim

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

K Kim

http://www.w3.org/2001/XMLSchema#string

K-T Jang

http://www.w3.org/2001/XMLSchema#string

M H Sim

http://www.w3.org/2001/XMLSchema#string

N K D Kim

http://www.w3.org/2001/XMLSchema#string

S T Kim

http://www.w3.org/2001/XMLSchema#string

S Y Kim

http://www.w3.org/2001/XMLSchema#string

W Park

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Sunitinib therapy for melanoma patients with KIT mutations.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The role of Kit-ligand in melanocyte development and epidermal homeostasis

Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

WNT signalling pathways as therapeutic targets in cancer

Ba/F3 cells and their use in kinase drug discovery.

P2888

s12094-017-1662-x

P31

scholarly article

P356

10.1007/S12094-017-1662-X

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28421416

http://www.w3.org/2001/XMLSchema#string